Published in Nat Methods on February 07, 2010
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
Induced pluripotency: history, mechanisms, and applications. Genes Dev (2010) 4.89
Direct reprogramming of mouse fibroblasts to neural progenitors. Proc Natl Acad Sci U S A (2011) 3.93
Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res (2011) 3.58
Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest (2011) 2.69
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation (2013) 2.57
Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A (2011) 2.51
Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clin Invest (2011) 2.23
Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci (2011) 2.09
A robust system for production of minicircle DNA vectors. Nat Biotechnol (2010) 1.95
Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. J Mol Cell Cardiol (2011) 1.93
Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood (2011) 1.92
Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res (2012) 1.84
Efficient feeder-free episomal reprogramming with small molecules. PLoS One (2011) 1.79
Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem (2010) 1.59
Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am J Respir Crit Care Med (2014) 1.53
Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. Sci Rep (2012) 1.42
MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells (2013) 1.41
Induced pluripotent stem cells and senescence: learning the biology to improve the technology. EMBO Rep (2010) 1.38
Reprogramming of mouse and human somatic cells by high-performance engineered factors. EMBO Rep (2011) 1.38
Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc (2013) 1.36
Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood (2011) 1.34
Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc (2010) 1.30
Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. Cell Stem Cell (2012) 1.23
Effects of ionizing radiation on self-renewal and pluripotency of human embryonic stem cells. Cancer Res (2010) 1.23
Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS One (2012) 1.20
Nonviral direct conversion of primary mouse embryonic fibroblasts to neuronal cells. Mol Ther Nucleic Acids (2012) 1.20
Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. Cell Res (2012) 1.19
Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov (2015) 1.18
Derivation of human induced pluripotent stem cells for cardiovascular disease modeling. Circ Res (2011) 1.17
A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol (2016) 1.16
Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Res Ther (2013) 1.14
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol (2016) 1.13
Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins. PLoS One (2010) 1.13
Integration-free iPS cells engineered using human artificial chromosome vectors. PLoS One (2011) 1.13
Technological overview of iPS induction from human adult somatic cells. Curr Gene Ther (2013) 1.13
Nonintegrating knockdown and customized scaffold design enhances human adipose-derived stem cells in skeletal repair. Stem Cells (2011) 1.11
Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. Circ Res (2014) 1.09
Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol (2012) 1.09
Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics (2012) 1.08
Assessing iPSC reprogramming methods for their suitability in translational medicine. J Cell Biochem (2012) 1.07
Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors. PLoS One (2013) 1.06
Comparative analysis of targeted differentiation of human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells reveals variability associated with incomplete transgene silencing in retrovirally derived hiPSC lines. Stem Cells Transl Med (2013) 1.06
Adipose tissue stem cells: the great WAT hope. Trends Endocrinol Metab (2012) 1.05
Pluripotent stem cell energy metabolism: an update. EMBO J (2014) 1.05
Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun (2014) 1.04
Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res (2011) 1.02
Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening. Stem Cell Res Ther (2013) 1.01
Growth factor-activated stem cell circuits and stromal signals cooperatively accelerate non-integrated iPSC reprogramming of human myeloid progenitors. PLoS One (2012) 1.01
Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors. Stem Cells Transl Med (2013) 1.00
Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther (2011) 1.00
Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol (2011) 1.00
A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards. J Cardiovasc Transl Res (2012) 1.00
Efficient generation of fully reprogrammed human iPS cells via polycistronic retroviral vector and a new cocktail of chemical compounds. PLoS One (2011) 0.99
Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc Natl Acad Sci U S A (2014) 0.98
Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol (2013) 0.98
Supercoiled Minivector DNA resists shear forces associated with gene therapy delivery. Gene Ther (2011) 0.98
Sleeping Beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. Nucleic Acids Res (2012) 0.98
Experimental approaches for the generation of induced pluripotent stem cells. Stem Cell Res Ther (2010) 0.97
A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine. Nat Protoc (2012) 0.97
The aging signature: a hallmark of induced pluripotent stem cells? Aging Cell (2013) 0.96
Generation of induced pluripotent stem cells using site-specific integration with phage integrase. Proc Natl Acad Sci U S A (2010) 0.95
Rapid and efficient conversion of integration-free human induced pluripotent stem cells to GMP-grade culture conditions. PLoS One (2014) 0.94
Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem Cells Transl Med (2013) 0.93
Progress in the reprogramming of somatic cells. Circ Res (2013) 0.92
Mechanistic insights into reprogramming to induced pluripotency. J Cell Physiol (2011) 0.92
Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration. Semin Ophthalmol (2011) 0.92
Regenerating functional heart tissue for myocardial repair. Cell Mol Life Sci (2012) 0.92
Footprint-free human induced pluripotent stem cells from articular cartilage with redifferentiation capacity: a first step toward a clinical-grade cell source. Stem Cells Transl Med (2014) 0.92
All roads lead to induced pluripotent stem cells: the technologies of iPSC generation. Stem Cells Dev (2014) 0.91
Stem cell sources for vascular tissue engineering and regeneration. Tissue Eng Part B Rev (2012) 0.91
Concise review: Human cell engineering: cellular reprogramming and genome editing. Stem Cells (2012) 0.90
Construction and characterization of an in-vivo linear covalently closed DNA vector production system. Microb Cell Fact (2012) 0.90
Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency. Sci Rep (2015) 0.90
Pathological ventricular remodeling: therapies: part 2 of 2. Circulation (2013) 0.90
From "ES-like" cells to induced pluripotent stem cells: a historical perspective in domestic animals. Theriogenology (2014) 0.89
Site-specific recombinase strategy to create induced pluripotent stem cells efficiently with plasmid DNA. Stem Cells (2011) 0.89
New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells. Hum Gene Ther (2013) 0.89
Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility. Prog Biophys Mol Biol (2012) 0.89
Vectorology and factor delivery in induced pluripotent stem cell reprogramming. Stem Cells Dev (2014) 0.88
Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells. J Hematol Oncol (2014) 0.88
Thinking outside the liver: induced pluripotent stem cells for hepatic applications. World J Gastroenterol (2013) 0.88
Stem cell-derived islet cells for transplantation. Curr Opin Organ Transplant (2011) 0.88
Stem cells for the treatment of neurodegenerative diseases. Stem Cell Res Ther (2010) 0.88
A novel luciferase fusion protein for highly sensitive optical imaging: from single-cell analysis to in vivo whole-body bioluminescence imaging. Anal Bioanal Chem (2014) 0.87
Reprogramming with Small Molecules instead of Exogenous Transcription Factors. Stem Cells Int (2015) 0.87
Development of poly(β-amino ester)-based biodegradable nanoparticles for nonviral delivery of minicircle DNA. ACS Nano (2013) 0.87
Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review. JAMA Cardiol (2016) 0.86
Integration-free methods for generating induced pluripotent stem cells. Genomics Proteomics Bioinformatics (2013) 0.86
Aged iPSCs display an uncommon mitochondrial appearance and fail to undergo in vitro neurogenesis. Aging (Albany NY) (2014) 0.86
DNA ministrings: highly safe and effective gene delivery vectors. Mol Ther Nucleic Acids (2014) 0.85
Efficient germ-line transmission obtained with transgene-free induced pluripotent stem cells. Proc Natl Acad Sci U S A (2014) 0.85
Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol (2016) 0.85
Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells. Stem Cells Transl Med (2015) 0.85
Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? EMBO Mol Med (2015) 0.85
Methods of induced pluripotent stem cells for clinical application. World J Stem Cells (2015) 0.85
Achievements and challenges in bioartificial kidney development. Fibrogenesis Tissue Repair (2010) 0.84
Cellular reprogramming employing recombinant sox2 protein. Stem Cells Int (2012) 0.84
Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system. Stem Cell Res Ther (2015) 0.84
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell (2007) 21.58
Human induced pluripotent stem cells free of vector and transgene sequences. Science (2009) 17.16
Generation of mouse induced pluripotent stem cells without viral vectors. Science (2008) 15.25
Induced pluripotent stem cells generated without viral integration. Science (2008) 13.38
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 13.02
Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell (2009) 11.65
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature (2009) 11.27
Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell (2009) 10.52
Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature (2009) 9.29
Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J (1994) 3.64
Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol (1991) 3.48
Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol (2006) 3.37
Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther (2003) 2.95
Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med (2000) 2.48
Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther (2005) 2.06
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Wound repair and regeneration. Nature (2008) 12.30
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature (2004) 8.36
Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen (2009) 7.29
Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 6.95
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
RNA interference in adult mice. Nature (2002) 5.33
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol (2007) 5.04
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther (2006) 4.64
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat Biotechnol (2004) 4.16
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol (2009) 3.70
Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell (2012) 3.66
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci U S A (2009) 3.57
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Human tRNA-derived small RNAs in the global regulation of RNA silencing. RNA (2010) 3.40
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med (2006) 3.39
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol (2003) 3.15
High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol (2005) 3.10
An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol (2011) 3.05
Germ-layer and lineage-restricted stem/progenitors regenerate the mouse digit tip. Nature (2011) 3.03
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther (2003) 2.95
The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol (2006) 2.94
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era. Circulation (2013) 2.87
Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS One (2010) 2.86
Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One (2008) 2.85
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 2.83
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest (2011) 2.69
The embrace device significantly decreases scarring following scar revision surgery in a randomized controlled trial. Plast Reconstr Surg (2014) 2.66
Imaging survival and function of transplanted cardiac resident stem cells. J Am Coll Cardiol (2009) 2.58
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation (2013) 2.57
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol (2002) 2.54
A transcriptome atlas of rice cell types uncovers cellular, functional and developmental hierarchies. Nat Genet (2009) 2.53
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther (2003) 2.49
MicroRNA profiling of human-induced pluripotent stem cells. Stem Cells Dev (2009) 2.44
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell (2011) 2.35
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell (2013) 2.33
MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation (2010) 2.32
Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol (2002) 2.31
Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle (2009) 2.30
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A (2008) 2.25
Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. Circ Cardiovasc Genet (2010) 2.24
Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation (2008) 2.22
Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation (2007) 2.21
Major deficit in the number of underrepresented minority academic surgeons persists. Ann Surg (2008) 2.20
Human cardiac progenitor cells engineered with Pim-I kinase enhance myocardial repair. J Am Coll Cardiol (2012) 2.18
Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation (2002) 2.14
Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation (2005) 2.12
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10